Literature DB >> 10516469

Epidemiology of hepatitis C virus in japan.

T Moriya1, T Koyama, J Tanaka, S Mishiro, H Yoshizawa.   

Abstract

Blood screening for hepatitis C virus (HCV) antibodies at Japanese Red Cross blood centers has indicated an age-dependent prevalence of HCV infection in the general population of Japan: the older the age, the higher the prevalence. The same pattern was corroborated by the sentinel study conducted in an HCV-endemic area. The high prevalence of HCV in the elderly is most likely due to a spread of HCV infection during the turmoil period just after World War II: in particular by illicit intravenous amphetamine abuse. Fortunately, however, since the rate of newly acquired infection is currently too low to influence HCV prevalence in each age group, the total number of HCV carriers (estimated to be 691,852 for the age group 20-64 years) would decrease spontaneously with generation takeover to approximately 50% of the current number during the decade to come.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516469     DOI: 10.1159/000024974

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  12 in total

1.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

2.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.

Authors:  Yasuhito Tanaka; Kousuke Hanada; Masashi Mizokami; Anthony E T Yeo; J Wai-Kuo Shih; Takashi Gojobori; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

Review 3.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

Review 4.  Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.

Authors:  Umberto Vespasiani-Gentilucci; Giovanni Galati; Paolo Gallo; Antonio De Vincentis; Elisabetta Riva; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

5.  Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

Authors:  H Yoshida; R Tateishi; Y Arakawa; M Sata; S Fujiyama; S Nishiguchi; H Ishibashi; G Yamada; O Yokosuka; Y Shiratori; M Omata
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

6.  On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.

Authors:  Hidetsugu Saito; Hirotoshi Ebinuma; Keisuke Ojiro; Kanji Wakabayashi; Mika Inoue; Shinichiro Tada; Toshifumi Hibi
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

Review 7.  Estimation of Cancer Burden Attributable to Infection in Asia.

Authors:  He Huang; Xiao-Feng Hu; Fang-Hui Zhao; Suzanne M Garland; Neerja Bhatla; You-Lin Qiao
Journal:  J Epidemiol       Date:  2015-09-19       Impact factor: 3.211

8.  Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients.

Authors:  Kazuo Tarao; Katsuaki Tanaka; Akito Nozaki; Akira Sato; Toshiya Ishii; Hirokazu Komatsu; Takaaki Ikeda; Tatsuji Komatsu; Shozo Matsushima; Kenji Oshige
Journal:  World J Hepatol       Date:  2017-04-18

9.  Changes in hepatitis C virus genotype distribution in Japan.

Authors:  H Toyoda; T Kumada; K Takaguchi; N Shimada; J Tanaka
Journal:  Epidemiol Infect       Date:  2014-03-05       Impact factor: 4.434

10.  Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.

Authors:  Kazuaki Chayama; Kazuo Notsumata; Masayuki Kurosaki; Ken Sato; Lino Rodrigues; Carolyn Setze; Prajakta Badri; Tami Pilot-Matias; Regis A Vilchez; Hiromitsu Kumada
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.